CoChat

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Resistance to chemotherapy can occur through a wide variety of mechanisms. Resistance to tyrosine kinase inhibitors (TKIs) often arises from kinase mutations-however, "off-target" resistance occurs but is poorly understood. Previously, we established cell line resistance models for three TKIs used in chronic myeloid leukemia treatment, and found that resistance was not attributed entirely to failure of kinase inhibition. Here, we performed global, integrated proteomic and transcriptomic profiling of these cell lines to describe mechanisms of resistance at the protein and gene expression level. We used whole transcriptome sequencing and SWATH-based data-independent acquisition mass spectrometry (DIA-MS), which does not require isotopic labels and provides quantitative measurements of proteins in a comprehensive, unbiased fashion. The proteomic and transcriptional data were correlated to generate an integrated understanding of the gene expression and protein alterations associated with TKI resistance. We defined mechanisms of resistance and two novel markers, CA1 and alpha-synuclein, that were common to all TKIs tested. Resistance to all of the TKIs was associated with oxidative stress responses, hypoxia signatures, and apparent metabolic reprogramming of the cells. Metabolite profiling and glucose-dependence experiments showed that resistant cells had routed their metabolism through glycolysis (particularly through the pentose phosphate pathway) and exhibited disruptions in mitochondrial metabolism. These experiments are the first to report a global, integrated proteomic, transcriptomic, and metabolic analysis of TKI resistance. These data suggest that although the mechanisms are complex, targeting metabolic pathways along with TKI treatment may overcome pan-TKI resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jproteome.9b00028

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ibsen K. H., 1961, Cancer Res., 21, 829

Cited by

See all 24

Metadata

Authors
Noel, B. M., Ouellette, S. B., Marholz, L., Dickey, D., Navis, C., Yang, T.-Y., Nguyen, V., Parker, S. J., Bernlohr, D., Sachs, Z., & Parker, L. L.
Affiliations
  • University of Minnesota (US)
  • Purdue University West Lafayette (US)
  • Cedars-Sinai Smidt Heart Institute (US)
Corresponding author
Parker, Laurie L.
Venue
Journal of Proteome Research
Published
2019-02-07
Volume
18
Issue
4
Pages
1842-1856
ISSN
  • 1535-3893 (ISSN-L)
  • 1535-3907
OpenAlex
W2914643359
Cited by
24
References
65
Citations by year
2026: 4 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 1 · 2020: 3 · 2019: 2
FWCI
1.94
Type
journal article
Language
en
Open access
Locations
  • Journal of Proteome Research (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA182546, R33CA183671, U54CA210190)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
tyrosine kinase inhibitor resistance, chronic myeloid leukemia, K562 cells, metabolic reprogramming, oxidative stress, hypoxia, glycolysis, pentose phosphate pathway, mitochondrial metabolism, CA1, alpha-synuclein, proteomic profiling, gene expression profiling, SWATH-MS
MeSH terms
Imatinib Mesylate, Dasatinib, Cell Survival, Humans, Protein-Tyrosine Kinases, Drug Resistance, Neoplasm, K562 Cells, Protein Kinase Inhibitors, Metabolome, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.